Agents Used in Antiretroviral Therapy

  • Authors: Philip Grant, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/10/19 (What's New)

Summary

  • Maraviroc, in combination with other antiretroviral agents, is indicated for adult patients infected with CCR5-tropic HIV only[FDA Maraviroc]
  • Maraviroc is a substrate for cytochrome P450 3A4 and dosed according to other agents in regimen (Table 17)[FDA Maraviroc]
  • In clinical trials, maraviroc-containing regimens have been associated with greater CD4+ cell count increases than comparator regimens, but clinical implications of this finding have not been elucidated

Action required

Keywords: Drug-Drug Interactions, Initial Antiretroviral Therapy, Management of Treatment-Experienced Patients, Special Populations, Treatment Complications, Tropism

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.